Sanofi-Aventis reaffirms safety profile of Ambien in response to media reports

By Lisa Kerner

Erie, Pa., March 20 - Sanofi-Aventis said it conducted a thorough analysis of Ambien for short-term insomnia, in response to media reports focused on rare occurrences of sleepwalking and sleep-related eating in patients who may also be taking the drug.

The company has not observed any significant change in the well-established safety profile of Ambien, according to a news release.

According to one source, the incidence of sleepwalking in the general adult population is approximately 4%, often coupled with a propensity for sleep-related eating disorders, the company said.

Sanofi-Aventis said it continues to closely monitor the safety profile of Ambien and communicates regularly with health authorities.

Located in Bridgewater, N.J., Sanofi-Aventis is a pharmaceutical company specializing in seven therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.